# EDGAR Filing Document

**Accession Number:** 0001503802
**File Stem:** 0001193125-26-059349
**Filing Date:** 2026-2
**Character Count:** 7718
**Document Hash:** c4ce568c2a3679382990b4aafb564cc5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-059349.hdr.sgml**: 20260219

**ACCESSION NUMBER**: 0001193125-26-059349

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 10

**CONFORMED PERIOD OF REPORT**: 20260218

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260219

**DATE AS OF CHANGE**: 20260219

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Karyopharm Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001503802
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 263931704
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36167
- **FILM NUMBER:** 26654359

**BUSINESS ADDRESS:**
- **STREET 1:** 85 WELLS AVENUE
- **STREET 2:** SECOND FLOOR
- **CITY:** NEWTON
- **STATE:** MA
- **ZIP:** 02459
- **BUSINESS PHONE:** 617-658-0600

**MAIL ADDRESS:**
- **STREET 1:** 85 WELLS AVENUE
- **STREET 2:** SECOND FLOOR
- **CITY:** NEWTON
- **STATE:** MA
- **ZIP:** 02459

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, DC 20549** 

**FORM** 8-K

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d)** 

**of the Securities Exchange Act of 1934** 

**Date of report (Date of earliest event reported):** **February 18, 2026**

Karyopharm Therapeutics Inc.

**(Exact Name of Registrant as Specified in Charter)** 

---

| | | | |
|:---|:---|:---|:---|
| Delaware | 001-36167 | 001-36167 | 26-3931704 |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission**<br>**File Number)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |
| 85 Wells Avenue**,** 2nd Floor<br>Newton**,** Massachusetts | 85 Wells Avenue**,** 2nd Floor<br>Newton**,** Massachusetts | 02459 | 02459 |
| **(Address of Principal Executive Offices)** | **(Address of Principal Executive Offices)** | **(Zip Code)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code:** (617) 658-0600

**(Former Name or Former Address, if Changed Since Last Report)** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u> General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange**<br>**on which registered** |
| Common Stock, $0.0001 par value | KPTI | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

<br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.07.** | **Submission of Matters to a Vote of Security Holders.** |

---

On February 18, 2026, Karyopharm Therapeutics Inc. (the "Company") held a Special Meeting of Stockholders (the "Special Meeting"). The following is a summary of the matters voted on at the Special Meeting.

---

| | | | |
|:---|:---|:---|:---|
| 1. | The Company's stockholders adopted and approved an amendment to the Company's Restated Certificate of Incorporation, as amended (the "Share Increase Amendment"), to increase the number of authorized shares of the Company's capital stock from 58,333,333 to 111,000,000 and the number of authorized shares of the Company's common stock from 53,333,333 to 106,000,000 (the "Authorized Shares Proposal"). The results of the stockholders' vote with respect to such adoption and approval were as follows: | The Company's stockholders adopted and approved an amendment to the Company's Restated Certificate of Incorporation, as amended (the "Share Increase Amendment"), to increase the number of authorized shares of the Company's capital stock from 58,333,333 to 111,000,000 and the number of authorized shares of the Company's common stock from 53,333,333 to 106,000,000 (the "Authorized Shares Proposal"). The results of the stockholders' vote with respect to such adoption and approval were as follows: | The Company's stockholders adopted and approved an amendment to the Company's Restated Certificate of Incorporation, as amended (the "Share Increase Amendment"), to increase the number of authorized shares of the Company's capital stock from 58,333,333 to 111,000,000 and the number of authorized shares of the Company's common stock from 53,333,333 to 106,000,000 (the "Authorized Shares Proposal"). The results of the stockholders' vote with respect to such adoption and approval were as follows: |
|  | **Votes For** | **Votes Against** | **Votes Abstaining** |
|  | 9436123 | 3213329 | 25465 |

---

The Company filed a Certificate of Amendment of Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on February 18, 2026 to effect the Share Increase Amendment.

---

| | | | |
|:---|:---|:---|:---|
| 2. | The Company's stockholders approved a proposal to adjourn the Special Meeting to a later date or dates, if necessary to permit further solicitation of proxies in the event that there are insufficient votes for the adoption and approval of the Authorized Shares Proposal. The results of the stockholders' vote with respect to such approval were as follows: | The Company's stockholders approved a proposal to adjourn the Special Meeting to a later date or dates, if necessary to permit further solicitation of proxies in the event that there are insufficient votes for the adoption and approval of the Authorized Shares Proposal. The results of the stockholders' vote with respect to such approval were as follows: | The Company's stockholders approved a proposal to adjourn the Special Meeting to a later date or dates, if necessary to permit further solicitation of proxies in the event that there are insufficient votes for the adoption and approval of the Authorized Shares Proposal. The results of the stockholders' vote with respect to such approval were as follows: |
|  | **Votes For** | **Votes Against** | **Votes Abstaining** |
|  | 10041437 | 2594322 | 39158 |

---

Adjournment of the Special Meeting was deemed unnecessary because there was a quorum present and there were sufficient votes to adopt and approve the Authorized Shares Proposal at the Special Meeting.

------

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | KARYOPHARM THERAPEUTICS INC. | KARYOPHARM THERAPEUTICS INC. |
| Date: February 19, 2026 | By: | /s/ Michael Mano |
|  |  | Michael Mano |
|  |  | Executive Vice President, Chief Legal Officer and Secretary |

---

------